25/08/2023 02:02 PM | Click to read full article
Perinatal depression, among the most common morbidities of pregnancy and the postnatal period, is a major public health challenge. Accurate data on the epidemiology of perinatal depression are crucial. The precise burden is unclear, but estimates of global prevalence range from 13% to 30%. The US Food and Drug Administration's approval of zuranolone, the first oral drug indicated for the treatment of postpartum depression is a welcome development.